Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch

Vaccine

Volumn 27, Issue SUPPL.6, 2009, Pages

  Glenn, Gregory M ^a   Thomas, D Nigel ^a   Poffenberger, Kimber L ^a   Flyer, David C ^a   Ellingsworth, Larry R ^a   Andersen, Bo H ^a   Frech, Sarah A ^a  

^a Intercell USA   (United States)

Author keywords

Adjuvant; Adjuvant patch; H5N1; LT; Pandemic influenza

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; INFLUENZA VACCINE; PLACEBO; SODIUM CHLORIDE;

ADJUVANT THERAPY; ADULT; ANTIBODY TITER; ARTICLE; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H5N1; INJECTION SITE PRURITUS; INJECTION SITE RASH; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SINGLE BLIND PROCEDURE; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; ENTEROTOXINS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 72049128598     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.031     Document Type: Article

References (34)

1. World now at the start of 2009 influenza pandemic; 2009. http://www.who.int/mediacentre/news/statements/2009/h1n1_pandemic_phase6_20090611/en/index.html. [accessed 25.09.09].
2. World Health Organization. Global pandemic influenza action plan to increase vaccine supply (2006), World Health Organization, Geneva, Switzerland
3. Lipsitch M., Lajous M., O'Hagan J.J., Cohen T., Miller J.C., Goldstein E., et al. Use of cumulative incidence of novel influenza A/H1N1 in foreign travelers to estimate lower bounds on cumulative incidence in Mexico. PloS One 4 9 (2009) e6895
4. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO; 2008. http://who.int/csr/disease/avian_influenza/country/cases_table_2008_05_28/en/index.html [accessed 05.06.08].
5. Hehme N., Colegate T., Palache B., and Hessel L. Influenza vaccine supply: building long-term sustainability. Vaccine 26 Suppl. 4 (2008) D23-D26
6. Hessel L. Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges. Influenza Other Resp Viruses 3 4 (2009) 165-170
7. Leroux-Roels I., and Leroux-Roels G. Current status and progress of prepandemic and pandemic influenza vaccine development. Exp Rev Vaccines 8 4 (2009) 401-423
8. Vogel F.R., Caillet C., Kusters I.C., and Haensler J. Emulsion-based adjuvants for influenza vaccines. Exp Rev Vaccines 8 4 (2009) 483-492
9. Nichol K.L., and Treanor J.J. Vaccines for seasonal and pandemic influenza. J Infect Dis 194 Suppl 2 (2006) S111-S118
10. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197 (2008) 667-675
11. Bresson J.-L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase 1 randomised trial. Lancet 367 (2006) 1657-1664
12. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
13. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 9540 (2006) 991-997
14. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
15. Frech S.A., DuPont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomized, double-blind, placebo-controlled field trial. Lancet 371 9629 (2008) 2019-2025
16. Frerichs D.M., Frech S.A., Flyer D.C., Yu J., and Glenn G.M. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 26 22 (2008) 2782-2787
17. McKenzie R., Bourgeois A.L., Frech S.A., Flyer D.C., Bloom A., Kazempour K., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25 18 (2007) 3684-3691
18. Frech S.A., Kenney R.T., Spyr C.A., Lazar H., Glück R., and Glenn G.M. Improved immune responses to influenza vaccination in the elderly using an immunostimulant patch. Vaccine 23 7 (2005) 946-950
19. Guebre-Xabier M., Hammond S.A., Ellingsworth L.R., and Glenn G.M. Immunostimulant patch enhances immune responses to influenza vaccine in aged mice. J Virol 78 14 (2004) 7610-7618
20. Guebre-Xabier M., Hammond S.A., Epperson D.E., Yu J., Ellingsworth L., and Glenn G.M. Immunostimulant patch containing heat labile enterotoxin from E. coli enhances immune responses to injected influenza vaccine through activation of skin dendritic cells. J Virol 77 9 (2003) 5218-5225
21. Glenn G.M., Flyer D.C., Ellingsworth L.R., Frech S.A., Frerichs D.M., Seid R.C., et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert review of vaccines 6 5 (2007) 809-819
22. Atmar R.L., Keitel W.A., Cate T.R., Munoz F.M., Ruben F., and Couch R.B. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 25 29 (2007) 5367-5373
23. Schwartz B., and Orenstein W.A. Prioritization of pandemic influenza vaccine: rationale and strategy for decision making. Curr Top Microbiol Immunol 333 (2009) 495-507
24. Giezeman K.M., Nauta J., de Bruijn I.A., and Palache A.M. Trivalent inactivated subunit influenza vaccine Influvac: 25-year experience of safety and immunogenicity. Vaccine 27 18 (2009) 2414-2417
25. Look J.L., Butler B., Al-Khalili M., Lai Y.-H., Frolov V., Zhang C., et al. The adjuvant patch: a universal dose sparing approach for pandemic and conventional vaccines. BioPharm Int.: Guide Vaccine Develop Manufact 20 August (Suppl.) (2007) 34-45
26. Clark TW, Pareek M, Hoschler K, et al. Trial of Influenza A (H1N1) 2009 monovalent MF59-adjuvanted vaccine-preliminary report. http://content.nejm.org/cgi/content/abstract/NEJMoa0907650v1. [accessed 16.09.09].
27. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response after one dose of a monovalent Influenza A (H1N1) 2009 vaccine-preliminary report. http://content.nejm.org/cgi/content/abstract/NEJMoa0907413v1 [accessed 16.09.09].
28. Levie K., Leroux-Roels I., Hoppenbrouwers K., Kervyn A.D., Vandermeulen C., Forgus S., et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198 5 (2008) 642-649
29. Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26 33 (2008) 4160-4167
30. Katz J.M., Lim W., Bridges C.B., Rowe T., Hu-Primer J., Lu X., et al. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 180 6 (1999) 1763-1770
31. Cate T.R., and Couch R.B. Live influenza A/Victoria/75 (H3N2) virus vaccines: reactogenicity, immunogenicity, and protection against wild-type virus challenge. Infect Immun 38 1 (1982) 141-146
32. Couch R.B., Douglas Jr. R.G., Fedson D.S., and Kasel J.A. Correlated studies of a recombinant influenza-virus vaccine, 3. Protection against experimental influenza in man. J Infect Dis 124 5 (1971) 473-480
33. Couch R.B., Webster R.G., Kasel J.A., and Cate T.R. Efficacy of purified influenza subunit vaccines and relation to the major antigenic determinants on the hemagglutinin molecule. J Infect Dis 140 4 (1979) 553-559
34. Puck J.M., Glezen W.P., Frank A.L., and Six H.R. Protection of infants from infection with influenza A virus by transplacentally acquired antibody. J Infect Dis 142 6 (1980) 844-849